Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
2.720
+1.315 (93.59%)
At close: Jan 30, 2026, 4:00 PM EST
2.750
+0.030 (1.10%)
After-hours: Jan 30, 2026, 7:38 PM EST

Tempest Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
13.6113.5511.6612.119.824.91
Research & Development
22.8128.4817.522.5317.1714.39
Operating Expenses
36.4242.0329.1634.6426.9919.3
Operating Income
-36.42-42.03-29.16-34.64-26.99-19.3
Interest Expense
-0.45-1.32-1.45-1.62-1.28-
Interest & Investment Income
0.821.51.120.55-0.09
Other Non Operating Income (Expenses)
-----0.03-
Pretax Income
-36.05-41.84-29.49-35.71-28.3-19.21
Net Income
-36.05-41.84-29.49-35.71-28.3-19.21
Net Income to Common
-36.05-41.84-29.49-35.71-28.3-19.21
Shares Outstanding (Basic)
421100
Shares Outstanding (Diluted)
421100
Shares Change (YoY)
114.19%80.99%33.49%204.70%709.63%-44.17%
EPS (Basic)
-9.71-19.50-24.87-40.20-97.07-533.38
EPS (Diluted)
-9.71-19.50-24.87-40.20-97.07-533.38
Free Cash Flow
-33.4-33.46-27.53-31.63-26.09-19.07
Free Cash Flow Per Share
-9.00-15.59-23.21-35.61-89.49-529.46
EBITDA
-36.17-41.64-28.78-34-26.61-18.96
D&A For EBITDA
0.250.390.380.640.370.34
EBIT
-36.42-42.03-29.16-34.64-26.99-19.3
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q